Clinical Hospital Dubrava

At Clinical Hospital Dubrava in Zagreb, cardiovascular diseases are a major focus, with studies centered on atrial fibrillation, acute myocardial infarction, chronic heart failure, and broader atherosclerotic cardiovascular disease. These trials aim to improve prevention, reduce recurrent events, and evaluate new approaches for patients with high cardiovascular risk.

• Testing new therapies to lower stroke and heart attack risk
• Evaluating treatment options for heart failure and inflammation
• Studying better strategies for acute coronary syndromes and recurrent myocardial infarction

This area reflects a strong clinical interest in both urgent cardiac care and long-term disease control.

Research in digestive system diseases and nutritional and metabolic diseases includes Crohn’s disease, ulcerative colitis, non-alcoholic steatohepatitis, primary biliary cholangitis, and acute-on-chronic liver failure. The trials are designed to assess new treatments that may ease inflammation, protect liver function, and improve outcomes in chronic gastrointestinal and liver conditions.

• Evaluating therapies for inflammatory bowel disease
• Testing options for liver inflammation and fibrosis
• Improving care for severe liver failure and related complications

These studies show a broad effort to advance both symptom control and disease-modifying treatment in complex gastroenterology care.

The site also supports trials in hemic and lymphatic diseases and neoplasms, including acute myeloid leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, multiple myeloma, and myelofibrosis. The research is focused on improving survival, controlling disease progression, and finding better treatment combinations for blood cancers and related disorders.

• Studying new approaches for leukemia and lymphoma treatment
• Assessing therapies for relapsed or hard-to-treat blood cancers
• Exploring ways to reduce spleen size and symptom burden in myelofibrosis

These trials highlight an active role in advancing modern oncology and hematology research.

Clinical research at the hospital includes respiratory tract diseases and immune system diseases, with studies in asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and progressive fibrosing interstitial lung disease. There is also interest in inflammatory conditions where the immune system plays a central role, aiming to improve disease control and lung function.

• Testing new treatments for uncontrolled asthma and COPD
• Evaluating therapies for progressive lung fibrosis
• Studying immune-driven inflammation in chronic respiratory disease

These projects combine pulmonology and immunology to address conditions that can strongly affect daily breathing and quality of life.

Another important research area involves immune system diseases, nutritional and metabolic diseases, and pathological conditions, including immunoglobulin A nephropathy, severe hypertriglyceridemia, and bleeding complications linked to anticoagulant use. The trials aim to improve kidney protection, lower metabolic risk, and support safer management of patients who need blood-thinning treatment.

• Evaluating kidney-focused therapies for IgA nephropathy
• Testing treatments to lower triglycerides and reduce cardiovascular risk
• Assessing ways to prevent or control clinically relevant bleeding

At Clinical Hospital Dubrava, this research brings together nephrology, metabolism, and hemostasis in studies aimed at safer and more effective care.

The site’s trial portfolio also extends to nervous system diseases, bacterial infections and mycoses, female and male urogenital diseases, and stomatognathic diseases. Research topics include epilepsy, complicated urinary tract infection, and oral bleeding prevention, showing a wide clinical scope beyond the main specialty of cardiology.

• Studying new options for refractory epilepsy and seizure control
• Evaluating treatments for complicated urinary tract infections
• Improving prevention of oral bleeding in patients on anticoagulants

These studies demonstrate a diverse research environment with attention to both common and highly specialized patient needs.